VicTrack Rides With Juniper Networks on Network Refresh Journey to Fuel Business Growth
Juniper-powered solutions enable VicTrack to build on its wide transportation network to provide leading communications…
5 years ago
Wire Stories
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials…
5 years ago
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
- Durable Responses Observed in Second Cohort of Patients in Pivotal EV-201 Trial of PADCEV…
5 years ago
Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Results of the Phase III AENEAS trial, to be presented at ASCO 2021, demonstrate better…
5 years ago
KE Holdings Inc. Announces First Quarter 2021 Unaudited Financial Results
BEIJING--(BUSINESS WIRE)--KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE), a leading integrated online and…
5 years ago
Digi Relocates Australian Headquarters to Milton to Bolster Exponential Growth and Opportunities
Newly renovated facility in Milton will drive collaboration, and engineering leadership to re-affirm market-leading position…
5 years ago
Labcorp to Expand Bioanalytical Services With Integrated Laboratory in Singapore
New Laboratory Grows Asia-Pacific Operations BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences…
5 years ago
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
– OPTIC Trial Evaluating Response-Based Dosing Regimens of ICLUSIG for the Treatment of Resistant /…
5 years ago
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
? Mobocertinib, an Oral Targeted Therapy, Demonstrated a Median Overall Survival of 24 Months, and…
5 years ago
Sugarbud Announces Second Consecutive Positive EBITDA Result for Q1 2021, Filing of First Quarter Financial Results and Corporate Update
CALGARY, Alberta, May 19, 2021 (GLOBE NEWSWIRE) -- Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.DB,…
5 years ago